StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15

Benzinga · 2d ago
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.